Guardant Health shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and announced a $40 price target.
Portfolio Pulse from Benzinga Newsdesk
Citigroup upgraded Guardant Health's stock from Neutral to Buy and set a $40 price target, causing the shares to trade higher.
May 26, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health's stock upgraded to Buy by Citigroup with a $40 price target, leading to higher trading.
Citigroup's upgrade from Neutral to Buy and the announcement of a $40 price target positively impacts Guardant Health's stock. This news increases investor confidence in the company, leading to higher trading and potential short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100